American Journal of Cardiology
Volume 103, Issue 3 , Pages 387-392 , 1 February 2009

Effect of Combination Nicotinic Acid and Gemfibrozil Treatment on Intermediate Density Lipoprotein, and Subclasses of Low Density Lipoprotein and High Density Lipoprotein in Patients With Combined Hyperlipidemia

  • H. Robert Superko, MD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • Mercer University College of Pharmacy and Health Sciences, Atlanta, Georgia
    • Cholesterol, Genetics, and Heart Disease Institute, Portola Valley, California
    • Corresponding Author InformationCorresponding author: Tel: 678-843-6052; fax: 678-843-6051
    • ,
  • Brenda C. Garrett, RN

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • ,
  • Spencer B. King III, MD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • Mercer University College of Pharmacy and Health Sciences, Atlanta, Georgia
    • ,
  • Kathryn M. Momary, PharmD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • Mercer University College of Pharmacy and Health Sciences, Atlanta, Georgia
    • ,
  • Nicolas A. Chronos, MD

      Affiliations

    • Saint Joseph's Translational Research Institute, Atlanta, Georgia
    • ,
  • Peter D. Wood, PhD, DSc

      Affiliations

    • Stanford University School of Medicine, Stanford, California

Received 30 May 2008 ,Revised 12 September 2008 ,Accepted 12 September 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was supported by Parke-Davis Pharmaceuticals, Warner-Lambert Company, Morris Plains, New Jersey, and the Cholesterol, Genetics, and Heart Disease Institute, Portola Valley, California.

PII: S0002-9149(08)01712-8

doi: 10.1016/j.amjcard.2008.09.103

American Journal of Cardiology
Volume 103, Issue 3 , Pages 387-392 , 1 February 2009

Article Tools

* Image Usage & Resolution